Literature DB >> 7398676

Binding of Tienilic acid (Diflurex) to human plasma proteins and erythrocytes.

C Plessas, A Benakis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398676     DOI: 10.1007/BF03189453

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


× No keyword cloud information.
  8 in total

1.  Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins and other blood components.

Authors:  M H Bickel
Journal:  J Pharm Pharmacol       Date:  1975-10       Impact factor: 3.765

Review 2.  [Plasma protein binding. Review].

Authors:  I von Schwarzenfeld
Journal:  Pharmazie       Date:  1974-08       Impact factor: 1.267

Review 3.  Methodological aspects of the evaluation of the binding of drugs to plasma and tissue proteins.

Authors:  J P Tillement; E Albengres; S Urien
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

4.  Ticrynafen: kinetics, protein binding, and effects on serum and urinary uric acid.

Authors:  A J Wood; P Bolli; H J Waal-Manning; F O Simpson
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

5.  Ticrynafen effect on warfarin protein binding in human serum.

Authors:  J T Slattery; G Levy
Journal:  J Pharm Sci       Date:  1979-03       Impact factor: 3.534

6.  Differences in the protein binding of several drugs and bilirubin in serum and heparinized plasma of rats.

Authors:  U W Wiegand; J T Slattery; K L Hintze; G Levy
Journal:  Life Sci       Date:  1979-07-30       Impact factor: 5.037

7.  Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent.

Authors:  M Nemati; M C Kyle; E D Freis
Journal:  JAMA       Date:  1977-02-14       Impact factor: 56.272

8.  Binding of tienilic acid (Diflurex) to human serum albumin and to plasma of normal subjects and uraemic patients.

Authors:  J Prandota; J P Tillement; P d'Athis; T Drüeke; S Digiulio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.